B cells in systemic autoimmune disease: Recent insights from Fas-deficient mice and men

Current Opinion in Immunology

Volumn 8, Issue 6, 1996, Pages 852-859

  Elkon, Keith B ^a   Marshak Rothstein, Ann ^b  

^a Department of Obstetrics Gynecology   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; FAS ANTIGEN; GLYCOPROTEIN GP 39; IMMUNOGLOBULIN RECEPTOR; INTERLEUKIN 4;

APOPTOSIS; AUTOIMMUNITY; B LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; HUMAN; MOUSE; NONHUMAN; REVIEW;

EID: 0030459465     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(96)80015-X     Document Type: Article

References (64)

1. Watanabe-Fukunaga R, Brannan Cl, Copeland NG, Jenkms NA, Nagata S: Lymphoproliferative disorder in mice explained by defects in Fes antigen that mediates apoptosis. Nature 1992, 356:314-317
2. Adachi M, Watanabe-Fukunaga R, Nagata S: Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of Ipr mice. Proc Natl Acad Sci USA 1993, 90:1756-1760.
3. Takahashi T, Tanaka M, Srannan Cl, Jenkins NA, Copeland NG, Suda T, Nagata S: Generalized lymphoproliferative disease in mice caused by a point mutation in the Fas ligand. Cell 1994, 76:969-976.
4. Lynch DH, Watson M, Alderson MR, Baum PR, Miller RE, Tough T, Gibson M, Davis-Smith T, Smith CA, Hunter K et al.: The mouse Fas-ligand gene is mutated in gid mice and is part of the TNF family gene cluster Immunity 1994, 1:131-136.
5. Good now CG: Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires Proc Natl Acad Sci USA 1996, 93:2264-2271.
6. Mandik L, Nguyen K-A, Erikson J: Fas receptor expression on B-lineage cells. Eur J Immunol 1995, 25:3148-3154.
7. Onel K, Tucek-Szabo CL, Ashany D, Lacy E, Nikolic-Zugic J, Elkon KB: Expression and function of the murine CD95/Fas/Apo-1 receptor in relation to B cell ontogeny, Eur J Immunol 1995, 25:2940-2947.
8. Carsalti R, Lohler G, Lamers MC: Transitional B cells are the target of negative selection in the B cell compartment. J Exp Med 1995, 181:2129-2140.
9. Rathmell JC, Goodnow CC: Effects of the Ipr mutation on elimination and inactivation of self-reactive B cells. J Immunol 1994, 153:2831-2842.
10. k Ipr mice. This report provides further evidence that central tolerance mechanisms in Ipr mice are intact.
11. Chen C, Nagy Z, Radic MZ, Hardy RR, Huszar D, Camper SA, Weigert M: The site and stage of anti-DNA B cell deletion. Nature 1995, 373:252-255. The authors demonstrate that DNA-reactive B cells car be deleted in the bone marrow at a pre-B to immature B transitional stage by using heavy chain only lg Tg mice bred onto mice with an inactivated JH locus. It will be important to determine whether the Ipr mutation disrupts central tolerance induction in this system.
12. Erikson J, Radic MZ, Camper SA, Hardy RR, Carmack C, Weigert M: Expression of anti-DNA imrnunoglobulin transgenes in non-autoimmune mice. Nature 1991, 349:331-334.
13. Roark JH, Kuntz CL, Nguyen K-A, Caton AJ, Erikson J: Breakdown of B cell tolerance in a mouse model of systemic lupus erythematosus. J Exp Med 1995. 181:1157-1167. MRL/lpr mice inheriting a heavy chain Tg associated with DNA-reactive autoantibodies use this heavy chain to make anti-dsDNA autoantibodies that give a homogeneous nuclear staining pattern; BALB/c mice inheriting the same trarsgene do not. This study indicates that certain autoreactiva B specificities which are eliminated in normal mice are not eliminated in Fasdeficient mice.
14. Cyster JG, Hartley SB, Goodnow CC: Competition for follicular niches excludes self-reactive B cells from the recirculating B cell repertoire. Nature 1994, 371:339-395.
15. Fulcher DA, Lyons AB, Korn SJ, Cook MC, Loeda C, Parish C, Fazekas de St Groth B, Basten A: The fate of self-reactive B cells depends primarily on the degree of antigen receptor engagement and availability of T cell help. J Exp Med 1996, 183:2313-2238. The authors carefully analyze the functional properties of anti-HEL Tg B cells in mice that express sHEL when the anti-HEL Tg B cells either constitute a small minority or the vast majority of the recirculating B cell pool, They show that the increased survival of Tg B cells in the latter case can be attributed to decreased levels of circulating sHEL. This report damonstrates how relatively subtle changes in self-antigen expression can have significant repercussions on tolerance induction.
16. Hannum LG, Donghui N, Haberman AM, Weigert MG, Shlomchik MJ: A disease-related RF autoantibody is not toleized in a normal mouse: implications for the origins of autoantibodies in autoimmune disease. J Bip Med 1996, 184:1269-1278.
17. + T cells to lymphoproliferation and autoantibody production in MRL-lpr/lpr mice. J Exp Med 1988, 167:1713-1718.
18. Jabs DA, Burek CL, Hu Q, Kupper RC, Lee B, Prendergast RA: Anti-CD4 monoclonal antibody therapy suppresses autoimmune disease in MRL/Mp-/pr//pr mice. Cell Immunol 1992, 141:496-507.
19. Jevnikar AM, Grusgy MJ, Glimcher LH: Prevention of nephritis in major histocompaubility complex class ll-deficient MRL-fpr mice. J Exp Med 1994, 179:1137-1143.
20. Koh D-R, Ho A, Rahgmtulla A, Fung-Leung W-P, Griesser H, Mak T-W: Murine lupus in MRL/fpr mice lacking CD4 or CDS cells. Eur J Immunol 1995, 25:2558-2562
21. Maldonado MA, Eisenberg RA, Rober E, Cohen PL, Kotzin BL: Greatly reduced lymphoproliferation in Ipr mice lacking major histocompatibility complex class I. J Exp Med 1995, 181:641-648. In the absence of MHC class I selected T cells, B6//pr mice shewed greatly reduced lymphadenopathy, a dramatically decreased number of double-negative T cells, and reduced titers of IgG autoantibodies.
22. + cells In /pr//pr mice lacking beta-2 microglobulin. J tmmunol 1995, 154:2063-2074,
23. Christianson GJ, Blankenburg RL, Dutfy TM, Panka D, Roths JB. Marshak-Rothstein A, Roopenian DC: β2-microglobulin dependence of the lupus-like autoimmune syndrome of MRL-Ipr mice. J Immunol 1996, 156:4932-4939.
24. Gisse T, Davidson EF; Chronic treatment of C3H-lpr/lpr and C3H-gld/gld mice with anti-CDS monoclonal antibody prevents the accumulation of double negative T cells but not autoantibody production. J Immunol 1994, 152:2000-2010.
25. 2-microglobulin.
26. Peng SF, Madaio MP, Hughes DPM, Crispe IN, Owen MJ, Wen L, Hayday AC, Craft J: Murine lupus in the absence of αβ T cells. J Immunol 1998, 156:4041-4049.
27. Eisenberg RA, Sobel ES, Reap EA, Halpern MD, Cohen PL: The role of B cell abnormalities in the systemic autoimmune syndromes of Ipr and gId mice. Sem Immunol 1994, 6:49-54.
28. + B cells to produce lupus autoantibodies in vivo. Eu r J Immunol 1996, 25:3412-3417
29. Ju S-T. Panka DJ, Cui H, Ettinger R, EI-Khatib M, Sherr DH, Stanger BZ, Marshak-Rotshtein A: Fas(CD95)/FasL interactions required for programmed cell death after T-celt activation. Nature 1995, 373:444-448.
30. Van Parijs L, Abbas AK: Role of Fas-mediated cell death in the regulation of immune responses. Curr Opin Immunol 1995, 8:355-361
31. Mohan C, Adams S, Stanik V, Datta SX: Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 1993, 177:1367-1381.
32. Desai-Mehta A, Mao C, Rajagopalan S, Robinson T, Datta SK: Structure and specificity of T cell receptors expressed by potentially pathogenic anti-DNA autoantibody -inducing T cells in human lupus. J Clin Invest 1995, 95:531-541. This report further establishes an important role for nijcleosome-specific T cells in the etiology of SLE
33. Monestier M, Novlck KE: Specificities and genetic characteristics of nucleosome-reactive antibodies from autoimmune mice. Mol Immunol 1996, 33:99-99.
34. Mohan C, Shi Y, Laman JD, Datta SK: Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995, 154:1470-1480.
35. Rothstain TL, Wang JKM, Panka QJ, Foots LC, Wang Z, Stanger B, Cui H, Ju S-T, Marshak-Rothstein A: Protection against Fasdependent Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature 1995, 374:163-165. B cells activated by cross-linked CD40L alone upregutats Fas and become extremely sensitive to Fas-mediated apoptosis. Concurranl activation through CD40 and the slgM receptor also results in increased Fas expression but these cells are resistant to FasL-expressirig T cells. These data suggest that, in vivo, Fas-FasL interactions are a critical faclor in the elimination B cells that have failed to receive a complete signal through their antigen-specific receptor.
36. Schattner EJ, Elkon KB, Yoo D-H, Tumang J, Krammer PH, Crow MK. Friedman SM: CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J Exp Med 1995, 182:1557-1565.
37. Garrone P, Neidhardt E-M, Garcia E, Galibert L, Van Konten C, Banchereau J: Fas ligation induces apoptosis of CD40-activated human B lymphocytes. 1 Exp Med 1995, 182:1265-1273.
38. Wang J, Taniuchi I, Maekawa Y, Howard M, Cooper MD, Watanabe T: Expression and function of Fas antigen on activated murine B cells. Eur J Immunol 1996, 26:92-95.
39. + T cells. Nature 1995, 376:131-184. The authors demonstrate that anergic B cells can be specifically killed in vivo by FasL-expressing Th cells.
40. Jacobson BA, Panka DJ, Nguyen K-A, Erikson J, Abbas AK, Marshak-Rothstein A: Anatomy of autoantibody production: dominant localization of antibody producing cells to T cell zones in Fas deficient mice. Immunity 1995, 3:509-519. Immunohistochemical and in situ hybridization methodology is used to demonstrate that autoantibody production in Ipr mice is initially localised to the T-cell-rich inner periarteriolar lymphoid sheath of the spleen. This analysis suggests that FasL regulation of autoreactive B cells takes place outside of germinal centers.
41. Foote LC, Howard RG, Marshak-Rothstein A, Rothstein TL: IL-4 induces Fas-resistance in B cells. J Immunol 1996. 157:2749-2753. CD40L activated B cells can also be protected from Fas mediated apoptosis by concurrent exposure to IL 4. This observation provides another means by which Th2 cell activity can favor systemic autoimmune disease.
42. Richaud-Patin Y, Alcocer-Varela J, Llorente L: High levels of Th2 cytokine gene expression in systemic lupus erythematosus. Rev Invest Clin 1995, 47:267-272.
43. + lymphocytes delete activated macrophages through the Fes/APO-1 pathway. Prcc Natl Acad Sci USA 1995, 92:11225-11229. Activated macrophages are also sensitive to FasL-expressing effector cells and may be involved in the activation of autoreactive T cells in Fas-FasL deficient mice.
44. Richardson BC, Lalwani ND, Johnson KJ, Marks RM: Fas ligalion triggers apoptosis in macrophages but not endothelial cells. Eur J Immunol 1994, 24:2640-2645.
45. Um HD, Orenstein JM, Wahl SM: Fas mediates apoptosis in human monocytes by a reactive oxygen intermediate dependent pathway. J Immunol 1996, 156:3469-3477.
46. Ray SK, Putterman C, Diamond B: Pathogenic autoantibodies are routinely generated during the response to foreign antigen: a paradigm for autoimmune disease. P roc Natl Acad Sci USA 1996, 93:2019-2024. By fusing B cells from phosphocholine immunized mice to bcl-2 transfected myeloma cells, the authors were able to isolate a remarkably high frequency of DMA-reactive hybridomas. Comparable numbers of DNA-reactiva hybridomas were not obtained with a conventional fusion partner. These results indicate that autoreactive B cells can be generated by somatic mutation during the response to conventional antigen, but such B cells normal die unless rescued by the bcl-2 fusion partner.
47. Lagresle C, Bella C, Daniel PT, Krammer PH, Defrance T: Regulation of germinal center B cell differentiation. Role of the human APO-1/Fas (CD95) molecule. J Immunol 1995, 154:5746-5756. The authors showed that T cell stimulation of germinal center B cells resulted in the upregulation of Fas. The role of Fas in the selection of germinal center B cells is discussed.
48. Watanabe D, Takashi S Nagata S: Expression of Fas in B cells of the mouse germinal center and Fas-dependent killing of activated B cells. Int Immunol 1995, 7:1949-1956.
49. Choe J, Kirn H-S, Zhang X. Armitage RJ. Choi YS: Cellular and molecular factors that regulate the differentiation and apoptosis of germinal center B cells. J Immunol 1996, 157:1006-1016, Using a novel culture system containing a follicular dendritic cell line, the authors delineate a dual role for germinal center T cells. Early in the differentiation of germinal center B cells the B cells can be rescued from spontaneous apoptosis by CD40L; whereas later in the process. B cells can be killed via Fas-dependent apoptosis unless their Ig receptors have been effectively engaged.
50. Very DL, Panka DJ, Weissman D, Wysocki L, Manser T, Marshak-Rothstein A: Lack of connectivity between the induced and autoimmune repertoires of Ipr/lpr mice. Immunology 80:518-526,
51. Smith KG, Nossal CJ. Tarlington DM: Fas is highly expressed in the germinal center but is not required for regulation of the B-cell response to antigen. Proc Natl Acad Sci USA 1995, 92:11628-11632. B6/+ and B6/lpr mice were shown to respond comparably to hapten conjugated protein. The number of antibody-forming cells and memory B cells generated in the two strains were similar and sequence analysis of germinal center B cells revealed no evidence for the increased accumulation of low-affinity hapten-bindrng cells. These data indicate that the Ipr mutation does not significantly alter germinal center responses.
52. Mysler E, Bini P, Drappa J, Ramos P, Friadman SM, Krammar PH, Elkon KB: The apoptosis-1/Fas protein in human systemic lupus erythematosus. J Clin Invest 1994, 93:1029-1034.
53. Ohsaka S. Hara M. Harigai M, Fukusawa C, Kashiwazaki S: Expression and function of Fas antigen and Bel-2 in human systemic lupus erythematosus lymphocytes. Clin Immunol Immunopathcl 1994, 73:109-114.
54. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kieler MC, Barr PJ, Mount; JD: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994, 263:1759-1762.
55. Knipping E, Krammer PH, Onel KB, Lehman TJA Mysler E, Elkon KB: Levels of soluble APO-1/Fas/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum 1995, 38:1735-1737.
56. Goel N, Ulrich DT, St. Clair EW, Fleming JA, Lynch DH, Seldin MF: Lack of correlation between serum soluble Fas/Apo-1 levels and autoimmune disease. Arthritis Rheum 1995, 38:1738-1743.
57. Mountz JD, Pierson MC, Zhou T, Cheng J, Elkon KB, Hasunuma T, Nishioka K, Okumura K, Lin G, Song GG et al.: Fas expression in patients with autoimmune disease. Arthritis Rheum 1995, 38:127.
58. Caseino I, Fiucci G, Papoff G, Ruberi G: Three function soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 1995, 154:2706-2713.
59. Tanaka M, Suda T, Takahashi T, Nagata S: Expression of the soluble form of human Fas ligand in activated lymphocytes. EMBO J 1995, 14:1129-1135.
60. Canale VC, Smith CH: Chronic lymphadenapathy simulating malignant lymphoma. J Pediatr 1967, 70:891-899.
61. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middelton LA, Lin AY, Straber W, Lenardo MJ, Puck JM: Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995, 81 :935-946. This report provides a detailed analysis of the genetic defects and mechanism responsible for defective Fas function in humans with the Ipr syndrome. Dominant mutations in Fas were traced to clinically unaffected parents, arguing for a requisite digenic defect for clinical expression of disease.
62. Rieux Laucat F, Le Deist F, Hivroz C, Roberts IAG, Debatin KM, Fischer A, DeVillartay JP: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995, 268:1347-1349. See annotation [61**].
63. Drappa J, Vaishnaw AK, Sullivan KE, Chu Jl, Elkon KB: The Canale-Smith syndrome: an inherited autoimmune disorder associated with defective apoptosis and mutations in the Fas gene. N Engl J Med 1996, in press. Novel mutations of Fas in a clinically well defined syndrome are described. This study raises important clinical questions regarding the role of Fas in hepatitis, autoimmunity and neoplasia in humans.
64. Ozdemirli M, EI-Khatib M, Foote LC, Wang JKM, Marshak-Rothstem A, Rolhstein TL, Ju S-T: Fas(CD95)/FasL interactions regulate antigen-specific, MHC-restricted T/B cell proliferate responses. Eur J Immunol 1996, 26:415-419.